×

Amicus Therapeutics to Announce Full-Year 2014 Financial Results on March 3, 2015

CRANBURY, N.J., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, March 3, 2015 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2014.

The call with be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET on March 3, 2015. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 94757702.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

FOLD-G

CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 spellegrino@amicusrx.com

Source:Amicus Therapeutics, Inc.